Black Diamond Therapeutic... (BDTX)
1.44
0.08 (5.88%)
At close: Apr 17, 2025, 3:59 PM
1.45
0.69%
After-hours: Apr 17, 2025, 07:58 PM EDT
5.88% (1D)
| Bid | 1.31 |
| Market Cap | 81.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.68M |
| EPS (ttm) | -1.27 |
| PE Ratio (ttm) | -1.13 |
| Forward PE | -1.07 |
| Analyst | Buy |
| Ask | 1.45 |
| Volume | 661,988 |
| Avg. Volume (20D) | 3,225,203 |
| Open | 1.32 |
| Previous Close | 1.36 |
| Day's Range | 1.31 - 1.45 |
| 52-Week Range | 1.20 - 7.66 |
| Beta | 2.82 |
About BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penet...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2020
Employees 24
Stock Exchange NASDAQ
Ticker Symbol BDTX
Analyst Forecast
According to 5 analyst ratings, the average rating for BDTX stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 941.67% from the latest price.
Stock ForecastsNext Earnings Release
Black Diamond Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+2.38%
Black Diamond Therapeutics shares are trading high...
Unlock content with
Pro Subscription
6 months ago
-5.46%
Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer.
